Bristol Myers Squibb (CELG-RI) Work In Process (2010 - 2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Work In Process of $884.0 million for Q1 2013, up 22.61% year-over-year from $721.0 million in Q1 2012, and up 8.6% quarter-over-quarter from $814.0 million in Q4 2012.
Bristol Myers Squibb (CELG-RI) Work In Process (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Work In Process for 4 consecutive years, with $884.0 million the latest figure, recorded in Q1 2013.
- In Q1 2013, Work In Process rose 22.61% year-over-year to $884.0 million; the TTM figure through Mar 2013 stood at $884.0 million (up 22.61% YoY), while the FY2012 annual figure was $814.0 million, up 26.01% from the prior year.
- Work In Process rose to $884.0 million in Q1 2013 per CELG-RI's latest filing, from $814.0 million in the prior quarter.
- Across five years, Work In Process topped out at $884.0 million in Q1 2013 and bottomed at $608.0 million in Q4 2010.
- Historically, Work In Process has averaged $739.3 million across 4 years, with a median of $715.0 million in 2011.
- On a YoY basis, Work In Process climbed as much as 26.01% in 2012 and fell as far as 4.49% in 2012.
- Bristol Myers Squibb's Work In Process stood at $608.0 million in 2010, then advanced by 6.25% to $646.0 million in 2011, then grew by 26.01% to $814.0 million in 2012, then climbed by 8.6% to $884.0 million in 2013.
- Business Quant data shows CELG-RI's Work In Process at $884.0 million in Q1 2013, $814.0 million in Q4 2012, and $868.0 million in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.18 Bn | 632.42 Bn | 17.26 Bn |
| 2 | AbbVie | 470.13 Bn | 463.56 Bn | 12.70 Bn |
| 3 | Merck | 376.16 Bn | 369.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.69 Bn | 295.00 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.73 Bn | 252.83 Bn | 12.86 Bn |
| 6 | Amgen | 236.53 Bn | 222.54 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.21 Bn | 180.03 Bn | 6.22 Bn |
| 8 | Pfizer | 160.17 Bn | 148.47 Bn | 10.94 Bn |
| 9 | Gsk | 105.91 Bn | 101.75 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 884.00 Mn |
| Dec 31, 2012 | 814.00 Mn |
| Sep 30, 2012 | 868.00 Mn |
| Jun 30, 2012 | 755.00 Mn |
| Mar 31, 2012 | 721.00 Mn |
| Dec 31, 2011 | 646.00 Mn |
| Sep 30, 2011 | 709.00 Mn |
| Jun 30, 2011 | 698.00 Mn |
| Mar 31, 2011 | 690.00 Mn |
| Dec 31, 2010 | 608.00 Mn |